Foghorn Therapeutics price target lowered to 13 from 20 at H.C. Wainwright - Yahoo Finance

FHTX Stock  USD 4.98  0.07  1.43%   
Slightly above 56% of all Foghorn Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Foghorn Therapeutics suggests that some traders are interested. Foghorn Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Foghorn Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Foghorn Therapeutics price target lowered to 13 from 20 at H.C. Wainwright Yahoo Finance

Read at news.google.com
Google News at Macroaxis
  

Foghorn Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Foghorn Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Foghorn Therapeutics Fundamental Analysis

We analyze Foghorn Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Foghorn Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Foghorn Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

Foghorn Therapeutics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Foghorn Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Foghorn Therapeutics stock to make a market-neutral strategy. Peer analysis of Foghorn Therapeutics could also be used in its relative valuation, which is a method of valuing Foghorn Therapeutics by comparing valuation metrics with similar companies.

Peers

Foghorn Therapeutics Related Equities

PRLDPrelude Therapeutics   46.07   
0%
100.0%
STTKShattuck Labs   10.58   
0%
22.0%
GLUEMonte Rosa   6.45   
0%
14.0%
CGEMCullinan Oncology   5.94   
0%
12.0%
IPSCCentury Therapeutics   4.76   
0%
10.0%
MLYSMineralys Therapeutics,   4.31   
0%
9.0%
KYMRKymera Therapeutics   3.88   
0%
8.0%
RZLTRezolute   3.68   
0%
7.0%
STOKStoke Therapeutics   3.36   
0%
7.0%
CCCCC4 Therapeutics   2.60   
0%
5.0%
PMVPPmv Pharmaceuticals   0.67   
0%
1.0%
MNOVMediciNova   0.46   
0%
1.0%
EWTXEdgewise Therapeutics   0.06   
1.0%
0%
CSBRChampions Oncology   0.53   
1.0%
0%
NRIXNurix Therapeutics   1.05   
2.0%
0%
MOLNMolecular Partners   1.51   
3.0%
0%
ANEBAnebulo Pharmaceuticals   10.81   
23.0%
0%

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.